Literature DB >> 29510649

The effects of letrozole and clomiphene citrate on ligands expression of Wnt3, Wnt7a, and Wnt8b in proliferative endometrium of women with Polycystic ovarian syndrome.

Shayesteh Mehdinejadiani1,2, Fardin Amidi1,3, Mehdi Mehdizadeh4, Mahmood Barati5, Leili Safdarian3, Reza Aflatoonian6, Ashraf Alyasin3, Marzieh Aghahosseini3, Azar Pazhohan7, Parisa Hayat2, Farzaneh Mohammadzadeh Kazorgah8, Aligholi Sobhani1.   

Abstract

Polycystic ovarian syndrome (PCOS) is a common endocrinologic disorder in women of reproductive age characterized by polycystic ovaries, oligo/anovulation, and hyperandrogenism. Not only anovulation but also endometrial dysfunction can reduce fertility in PCOS patients. Wnt pathway is responsible for endometrial proliferation which be strongly regulated by estradiol. To determine the effects of clomiphene citrate (CC) and letrozole, we measured the expression of some main ligands of Wnt/β-catenin signaling including Wnt7a, Wnt3, and Wnt8b in the endometrial samples taken from PCOS women on day 12 of the menses who received 100 mg CC or 5 mg letrozole as well as from women without treatment. Significantly, the mean estrogen and progesterone concentration were lower and higher, respectively, in letrozole than CC. The mean endometrial thickness (ET) was significantly greater in letrozole compared to CC. Assessment of the mRNA and protein expression of Wnt7a, Wnt3, and Wnt8b showed significantly lower expression in CC than the letrozole and control groups. Collectively, letrozole provided a better molecular response in the endometrium of PCOS patients during the proliferative phase, similar to natural cycles, compared to CC. CC decreased the ligands expression of Wnt3, Wnt7a, and Wnt8b, resulting in endometrial dysfunction.

Entities:  

Keywords:  Polycystic ovary syndrome; Wnt ligands; clomiphene citrate; letrozole; tndometrium

Mesh:

Substances:

Year:  2018        PMID: 29510649     DOI: 10.1080/09513590.2018.1446934

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

1.  Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats.

Authors:  Zahra Shaaban; Amin Tamadon; Mohammad Reza Jafarzadeh Shirazi; Mohammad Javad Zamiri; Amin Derakhshanfar
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

2.  Effects of letrozole combined with human menopausal gonadotrophin in ovarian stimulation for intrauterine insemination cycles.

Authors:  Xiaoying Yu; Zhiwen Cao; Wenwen Hou; Weihua Hu; Guijun Yan
Journal:  Ann Transl Med       Date:  2019-12

3.  Identification of Potential Biomarkers of Polycystic Ovary Syndrome via Integrated Bioinformatics Analysis.

Authors:  Dongyong Yang; Na Li; Aiping Ma; Fangfang Dai; Yajing Zheng; Xuejia Hu; Yanqing Wang; Shu Xian; Li Zhang; Mengqin Yuan; Shiyi Liu; Zhimin Deng; Yi Yang; Yanxiang Cheng
Journal:  Reprod Sci       Date:  2020-10-16       Impact factor: 3.060

4.  Ovulation induction regimens are associated with a higher rate of livebirth after frozen single-blastocyst transfer among women with polycystic ovary syndrome.

Authors:  Yue Niu; Dingying Zhao; Yuhuan Wang; Lu Suo; Jialin Zou; Daimin Wei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-15       Impact factor: 6.055

5.  Cyclooxygenase-2 and β-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer.

Authors:  Lin Deng; Haiyan Liang; Yi Han
Journal:  Front Oncol       Date:  2020-02-21       Impact factor: 6.244

Review 6.  Therapeutic Potentials of Low-Dose Tacrolimus for Aberrant Endometrial Features in Polycystic Ovary Syndrome.

Authors:  Ahmad J H Albaghdadi; Frederick W K Kan
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.